{"anticipatedPostingDate":"2027-06","denomUnitsSelected":"Participants","description":"To determine the efficacy of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy in newly diagnosed advanced or recurrent endometrial cancer patients by assessment of TFST","reportingStatus":"NOT_POSTED","timeFrame":"Time elapsed from randomisation to first subsequent therapy or death. Assessed every 12 wks following treatment discontinuation, through study completion (up to 83 months)","title":"Time From Randomisation to First Subsequent Therapy or Death (TFST)","type":"SECONDARY"}